This product is a macrolide antibiotic, which has an inhibitory effect on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Peptostreptococcus, and Propionibacterium acnes. In addition, it also has an inhibitory effect on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.

It has high activity against protozoa and anaerobic bacteria and can inhibit most anaerobic bacteria; microaerophilic bacteria and Helicobacter pylori are sensitive to it; its anti-amoeba mechanism is to inhibit its redox reaction, causing the protozoa's nitrogen chain to break, thereby killing the protozoa.